NextGen Bioscience Inc. is a disease-treatment research organization whose primary focus is cancer therapy. Its main goal is to achieve a new generation of cancer treatments that will be effective against several forms of this deadly affliction.
New drugs and therapeutic procedures are being tested all the time by countless groups, as well as independent researchers across the globe. Cancer treatments now comprise the largest disease market in the world, and are expanding at an exponential rate. Estimated growth rates in the sector have been placed in excess of 20 percent per year. While the main intent behind this is the eradication of a disease that claims hundreds of thousands of lives annually, significant financial gains await the proprietary owners of an eventual cure.
On April 8th, NextGen Bioscience Inc. took an important step in that direction. It acquired a patent application for an exciting new process that has improved upon past methods of identifying and cleansing the body of undifferentiated cancer stem-cells. These cells are often what remain after conventional treatments destroy malignant tissues, and are the cause of re-occurring tumors. They can be likened to the roots of a weed that, even after the plant itself has been removed, maintain their hold in the soil, allowing a new weed to grow.
NextGen CEO, Konstantinos Kardiasmenos, stated, “Based on evidence that cancers such as breast cancer and prostate cancer proliferate primarily from cancer stem cells, this technology will be vital for both early diagnosis and identifying targets for a new generation of targeted therapeutic strategies.”
While NextGen certainly stands to potentially acquire significant monetary gain from such a breakthrough, we must remember that the true benefactors would be the millions of people suffering from the most serious illness in human history.
Let us hear your thoughts below: